IDWeek

Findings indicate that treatment interruptions are possible, with caveats.

Research indicates that influenza vaccine effectiveness was low but effective in preventing influenza-related hospitalization during the 2016-2017 flu season in Canada.

Investigators report the first real-world data on the safety and effectiveness of G/P for patients on opioid substitution therapy within the German Hepatitis C-Registry.

Keith Kaye, MD, MPH discusses the current successes and challenges in addressing multidrug-resistant infections, as well as expectations for how recommendations will change in the future.

Investigators find school-located influenza vaccination increased coverage and decreased school absence and influenza hospitalization.

Thomas Lodise, PharmD, PhD discusses the importance of practicing risk stratification and exploring combination therapeutic options in patients with drug-resistant infections.

In a Meet-the-Professors session at ID Week 2018, experts addressed strategies to check for drug-drug interactions, direct-acting antivirals for special populations, and the management of hepatitis C virus infection for persons who inject drugs.

Individuals with HIV who have been detained at the US border are far more likely to be released having had some consultation about their health and steps to improve their outlook compared with those who were detained several years ago.

New research suggests that flu vaccination setting is associated with vaccination timing.

A Dallas-based study found that an adult hospital with a universal screening policy was far more likely to provide screenings to high-risk patients aged 13 or older.

DOR/3TC/TDF demonstrates noninferior efficacy and safety compared with continuing other ART regimens in a phase 3 trial.

Kenneth Sherman, MD, PhD, discusses prevention measures for hepatitis B, managing co-infections of HIV and HCV, and recent developments to HCV screening processes

High-risk individuals, such as those with cardiopulmonary and other chronic conditions, are protected from flu-related hospitalizations with the vaccine.

Investigators analyzed data from PrEP-eligible patients at the New York City Health + Hospital/Bellevue which showed that women and minority patients were less likely to be prescribed PrEP for HIV prevention.

A South Korea meta-analysis found that, similarly to C. difficile, tuberculosis risk could be limited by the lipid-lowering agent.

Roche's investigative drug could become the first single-dose oral antiviral approved for the US market in December.

Community-onset cases still hovered around 45% of the annual cases, with the remainder being infections that developed once patients had been admitted to the hospital.

An oral influenza vaccine tablet protects against virus as well or better than an injectable quadrivalent vaccine in phase 2 trial.

Race and sex can play a role in the annual BMI gain for patients with HIV who are receiving certain antiretroviral therapy combinations.

Unvaccinated individuals can also benefit from the flu vaccine.

Study highlights differences in prescription of mental health medications for people living with HIV/AIDS.

In review of US-based infections during the 2016 outbreak, investigators found more telling indicators of the virus are patients' proximity to other infected patients, and their desire to be tested.

An intervention of scheduling an appointment and contacting the patient successfully increased re-engagement among patients with HIV who had not had a primary care visit in the previous 6 months.

Investigators have found the IIV4 vaccination to be as effective as IIV3-SD, while IIV3-HD was found to be more effective than IIV3-SD.

Approximately 30% of annual HIV infections are caused by the subset of individuals unaware of their serostatus, and HCV rates have nearly tripled since 2011.

The UN and WHO aim to reduce the burden of cholera globally by 90% reduction in deaths by 2030.

Learn more about the decrease in yellow fever vaccine production that will last until mid-2018.

Why is delafloxacin unique compared to other fluoroquinolones? Find out more.

As drug costs continue to rise, many are hoping generics will bring relief. But will they?

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the future for HIV drug prices.